Evidence map›Paper›PMID 39339288›Full record

ReviewMolecules (Basel, Switzerland)2024

Application of Intelligent Response Fluorescent Probe in Breast Cancer.

Anqi Sheng, Hao Zhang, Qing Li, Shu Chen, Qingshuang Wang

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anqi ShengCollege of Life Science and Technology, Changchun University of Science and Technology, Changchun 130013, China.
Hao ZhangCollege of Life Science and Technology, Changchun University of Science and Technology, Changchun 130013, China.
Qing LiTechnology Innovation Institute of Jilin Province, Changchun 130012, China.
Shu ChenTechnology Innovation Institute of Jilin Province, Changchun 130012, China.
Qingshuang WangCollege of Life Science and Technology, Changchun University of Science and Technology, Changchun 130013, China.

Funding

Science and Technology Department of Jilin Province 20220508062RC
6 · The paper itself

Abstract

As one of the leading cancers threatening women's lives and health, breast cancer is challenging to treat and often irreversible in advanced cases, highlighting the critical importance of early detection and intervention. In recent years, fluorescent probe technology, a revolutionary in vivo imaging tool, has gained attention in medical research for its ability to improve tumor visualization significantly. This review focuses on recent advances in intelligent, responsive fluorescent probes, particularly in the field of breast cancer, which are divided into five categories, near-infrared responsive, fluorescein-labeled, pH-responsive, redox-dependent, and enzyme-triggered fluorescent probes, each of which has a different value for application based on its unique biological response mechanism. In addition, this review also covers the strategy of combining fluorescent probes with various anti-tumor drugs, aiming to reveal the possibility of synergistic effects between the two in breast cancer treatment and provide a solid theoretical platform for the clinical translation of fluorescent probe technology, which is expected to promote the expansion of cancer treatment technology.

Indexed as

Breast NeoplasmsEarly Detection of CancerFluorescent DyesOptical ImagingAnimalsAntineoplastic AgentsBreastDrug SynergismFemaleHumansNanoparticle Drug Delivery SystemNanoparticlesOxidation-ReductionSpectroscopy, Near-InfraredTumor MicroenvironmentAntineoplastic AgentsFluorescent DyesNanoparticle Drug Delivery Systemapplicationbreast cancerfluorescent probessynthesis

Identifiers

PMID39339288
PMCPMC11434508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.